Kura Oncology, Inc. (KURA)

Kura Oncology is a clinical-stage biotech whose primary bull thesis rests on its menin inhibitor ziftomenib, a potential best-in-class asset targeting NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) — a high-unmet-need indication with accelerated approval potential. The 14-to-1 Buy-to-Hold analyst skew and a consensus price target implying ~160% upside reflect strong pipeline conviction following promising Phase 2 data. The key risk is binary: clinical or regulatory setbacks to ziftomenib's ongoing trials could materially impair the stock given the company's pre-profitability status and dependence on capital markets.

• Ziftomenib pivotal trial readout in NPM1-mutant AML — a positive result could support an NDA submission and trigger a significant re-rating
• Potential FDA Breakthrough Therapy or accelerated approval designation updates, which could compress the timeline to commercialization
• Partnership or licensing deal for ziftomenib or pipeline assets, which would validate the science and provide non-dilutive capital to extend the cash runway

• Binary clinical risk: a Phase 2/3 trial miss for ziftomenib in AML would likely cause a severe share price decline, as it is the lead asset underpinning the entire valuation
• Dilution risk: as a loss-making company with a negative forward P/E, Kura will likely require additional equity raises to fund operations, pressuring existing shareholders
• Competitive risk: multiple large-cap pharma companies (e.g., Syndax, Janssen) are developing competing menin inhibitors in the same AML indications, threatening market share before launch

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →